LNTH Lantheus Holdings, Inc.
Legal ·
Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit.
Lantheus closed the acquisition on July 21, 2025 and named Dr. Ludger Dinkelborg Head of Research and Development, effective August 1, 2025. The deal adds the Alzheimer's PET imaging agent Neuraceq.
Lantheus said on April 1, 2025 that it completed its acquisition of Evergreen Theragnostics, paying about $275 million in cash at closing. That is a $250 million upfront payment plus a $25 million milestone, and up to $727.5 million in further milestone payments remain possible.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $177.3 million | $168.1 million |
| Net income (loss) | $233.6 million | $312.4 million |
| Cash from operations | $390.1 million | $544.8 million |
| Cash and equivalents | $359.1 million | $912.8 million |
Our latest story on this, dated Oct 2, 2026: "Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters". The story links the filing or release it is based on. Read the story.
Lantheus Holdings, Inc. trades under the ticker LNTH on NASDAQ.
Lantheus Holdings, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for Lantheus Holdings, Inc. is 1521036. Its filings are on SEC EDGAR.
65,272,369 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Lantheus Holdings, Inc. under United States.
Our directory classifies Lantheus Holdings, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lantheus Holdings, Inc. is US5165441032.
aibio.space lists Lantheus Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lantheus Holdings, Inc. reported net income of $233.6 million for the fiscal year ended Dec 31, 2025, and generated $390.1 million of cash from operations, per its annual report to the SEC.
$177.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
$593.3 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Lantheus Holdings, dated Oct 2, 2026: "Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters". Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit. Source.
Our latest legal story, dated Oct 2, 2026: "Lantheus discloses three stockholder suits over its Curium merger and 16 demand letters". Defendants: Lantheus Holdings and unnamed Board members, per the 8-K. Two New York and one Massachusetts complaint allege proxy omissions; the company says they lack merit. Claims in lawsuits are allegations until a court rules. Source.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Announced a share repurchase program. SEC Form 8-K (Items 8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio